Last updated: February 24, 2026
What is the drug associated with NDC 68462-0135?
NDC 68462-0135 designates Pluvicto (lutetium Lu 177 vipivotide tetraxetan). It is an FDA-approved radioligand therapy indicated for adult patients with metastatic castration-resistant prostate cancer (mCRPC) targeting PSMA-positive lesions. Approved in March 2022, its mechanism involves delivering targeted radiation to prostate cancer cells.
Current Market Position
Pluvicto's market landscape is defined by:
- Indication: Treatment of mCRPC expressing prostate-specific membrane antigen (PSMA).
- Approval: FDA (March 2022); EMA approval follows.
- Competitors: Other radioligand therapies including Dr. Reddy's RLT (no direct competitor but similar class).
- Demand drivers: Increased prevalence of prostate cancer, improved detection via PSMA PET imaging, and limited first-line options for mCRPC.
Market Size and Growth Projections
Epidemiology and Market Size
Prostate cancer affects approximately 1.3 million men globally annually.[1] The castration-resistant subset accounts for about 10-15% of cases. Estimated U.S. market size:
| Parameter |
Value |
| Annual prostate cancer cases |
288,300 (CDC estimate 2021) |
| Castration-resistant prostate cancer (mCRPC) percentage |
10-15% of total cases |
| Estimated annual mCRPC cases |
28,830 – 43,245 |
| Patients eligible for radioligand therapy |
80-90% of mCRPC cases, considering PD-L1 status and PSMA expression |
Thus, the initial addressable US market is roughly 23,000 – 38,900 patients annually.
Market Growth Outlook
- The uptake of PSMA PET imaging expands diagnosis, leading to more eligible patients.
- Clinicians increasingly adopt radioligand therapy as a treatment option due to efficacy observed in trials.
- Growth factors include broadened indication scope and earlier use.
Revenue Estimates
Based on existing comparable niche therapies:
| Year |
Estimated U.S. Revenue (USD millions) |
Growth Rate |
Assumptions |
| 2023 |
150 |
— |
Launch year, limited penetration, initial uptake at 10-15% of addressable patients. |
| 2024-2025 |
250 – 350 |
20-25% annually |
Increased adoption, expanded payer coverage, clinical guidelines support. |
| 2026+ |
500+ |
Continuing growth |
Full market penetration, potential for label expansion, geographic expansion. |
Price Projections
Current Pricing and Reimbursement
- The wholesale acquisition cost (WAC) for Pluvicto is approximately $37,000 – $38,000 per dose.[2]
- Typical treatment involves multiple doses (generally two to four), with treatment cost reaching $80,000 – $150,000 per patient.
Competitive Pricing Analysis
| Therapy |
Price Range (USD) per Dose |
Doses |
Total Cost per Patient |
| Pluvicto |
37,000 – 38,000 |
2 – 4 |
74,000 – 152,000 |
| External radiotherapy (e.g., Radium-223) |
30,000 – 35,000 |
6 |
Around 200,000 |
Pluvicto offers a niche with potentially higher per-dose pricing due to its targeted mechanism and efficacy.
Market Penetration and Price Sensitivity
- Payers may negotiate discounts, especially as clinical data accumulates.
- reimbursement trends favor value-based agreements, with drug costs tied to clinical outcomes.
- Price increases are likely as manufacturing scales and competition remains limited.
Long-term Price Trends
- Introduction of biosimilars is unlikely in the near-term due to the unique radioactive drug manufacturing process.
- Prices are expected to stabilize around current levels unless new competitors emerge or regulatory policies tighten pricing controls.
Regulatory, Pricing, and Policy Environment
- The CMS and private insurers are developing coverage guidelines for radioligand therapies.
- As of 2023, no mandated discounts, but future adjustments might occur based on healthcare policy shifts.
- Expanding indications could trigger price adjustments, either upward for new uses or downward driven by payers.
Risks and Challenges Impacting Market and Pricing
- Regulatory delays or restrictions.
- Limited manufacturing capacity for radiopharmaceuticals.
- Competition from emerging therapies—both novel radioligands and other treatment modalities.
- Payer pushback on high per-treatment costs.
- Advances in alternative imaging or treatment techniques reducing reliance on radionuclide therapies.
Key Takeaways
- The overall U.S. market for NDC 68462-0135 (Pluvicto) is projected to reach $150 million in 2023, with substantial growth in subsequent years.
- The typical treatment cost per patient is $80,000 to $150,000, with prices likely to remain stable unless new competitors or policy changes arise.
- Adoption and revenues depend heavily on the expansion of PSMA diagnostics, clinical confidence, and payer coverage.
- As a niche, Pluvicto maintains limited but robust pricing power given its targeted mechanism and clinical profile.
FAQs
Q1: What is the primary indication for NDC 68462-0135?
Treatment of metastatic castration-resistant prostate cancer with PSMA-positive lesions.
Q2: What is the expected annual revenue for Pluvicto in the U.S.?
Approximately $150 million in 2023, with growth projected to exceed $500 million by 2026.
Q3: How does the pricing of Pluvicto compare to other prostate cancer therapies?
Per-dose pricing is comparable to other niche radioligand therapies but can be higher due to targeted delivery.
Q4: What factors could influence future prices?
Regulatory changes, competitive developments, payer negotiations, and indications expansion.
Q5: What are the main risks to market growth?
Limited manufacturing capacity, regulatory delays, competition, and reimbursement challenges.
References:
[1] Siegel, R. L., Miller, K. D., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33.
[2] IQVIA. (2023). Pricing data for radiopharmaceuticals. Retrieved from IQVIA reports.
